Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: An in vivo [(11)C](R)-PK11195-PET pilot study

Neurobiology of Disease

Volumn 65, Issue , 2014, Pages 203-210

  Giannetti, Paolo ^a   Politis, Marios ^a,b   Su, Paul ^a   Turkheimer, Federico ^b   Malik, Omar ^a   Keihaninejad, Shiva ^a   Wu, Kit ^a   Reynolds, Richard ^a   Nicholas, Richard ^a   Piccini, Paola ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Black holes; Microglia; Multiple sclerosis; Neurodegeneration; PK11195 PET

Indexed keywords

N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; RADIOLIGAND;

ADULT; AGED; ARTICLE; BLACK HOLE; CELL ACTIVATION; CELL ACTIVITY; CELL LOSS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHY SCANNER; CORRELATION ANALYSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BINDING; DRUG TISSUE LEVEL; EXPANDED DISABILITY STATUS SCALE; HUMAN; IN VIVO STUDY; INFLAMMATION; MICROGLIA; MICROGLIA ACTIVATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS;

BLACK HOLES; MICROGLIA; MULTIPLE SCLEROSIS; NEURODEGENERATION; PK11195-PET;

ADULT; AMIDES; DISEASE PROGRESSION; FEMALE; HUMANS; ISOQUINOLINES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS;

EID: 84894552855     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.01.018     Document Type: Article

References (43)

1. Banati R.B., et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000, 123(Pt 11):2321-2337.
2. Bitsch A., et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann. Neurol. 2001, 49:793-796.
3. Block M.L., et al. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
4. Breij E.C.W., et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63:16-25.
5. Brück W., et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol. 1997, 42:783-793.
6. Cagnin A., et al. In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol. Scand. Suppl. 2006, 185:107-114.
7. Cagnin A., et al. Positron emission tomography imaging of neuroinflammation. Neurotherapeutics 2007, 4:443-452.
8. Chen M.-K., et al. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain 2004, 127:1379-1392.
9. Gao H.-M., Hong J.-S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008, 29:357-365.
10. Gao Z., Tsirka S.E. Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis. Neurol. Res. Int. 2011, 9. (Article ID 383087). 10.1155/2011/383087.
11. Giugni E., et al. MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. Mult. Scler. 1997, 3:221-225.
12. Gunn R.N., et al. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 1997, 6:279-287.
13. Howell O.W., et al. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2010, 69:1017-1033.
14. Innis R.B., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
15. Kemp B.J., et al. NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes. J. Nucl. Med. 2006, 47:1960-1967.
16. Kremenchutzky M., et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006, 129:584-594.
17. Kutzelnigg A., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
18. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
19. Maeda J., et al. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res. 2007, 1157:100-111.
20. Magliozzi R., et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 2010, 68:477-493.
21. Masek M., et al. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status. Neuro Endocrinol. Lett. 2008, 29:461-466.
22. McDonald W.I., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
23. McMahon E.J., et al. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 2005, 11:335-339.
24. Nessler S., et al. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain 2007, 130:2186-2198.
25. O'Riordan J.I., et al. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult. Scler. 1998, 4:408-412.
26. Paolillo A., et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999, 53:751-757.
27. Politis M., et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 2012, 79:523-530.
28. Reynolds R., et al. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 2011, 122:155-170.
29. Rocca M.A., et al. Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions-a diffusion tensor MR study. J. Neurol. 2003, 250:456-460.
30. Schweitzer P.J., et al. PET tracers for the peripheral benzodiazepine receptor and uses thereof. Drug Discov. Today 2010, 15:933-942.
31. Shah F., et al. Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl. Med. Biol. 1994, 21:573-581.
32. Sicotte N.L. Magnetic resonance imaging in multiple sclerosis: the role of conventional imaging. Neurol. Clin. 2011, 29:343-356.
33. Simon J.H., et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000, 55:185-192.
34. Trapp B.D., et al. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 1999, 12:295-302.
35. Truyen L., et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996, 47:1469-1476.
36. Turkheimer F.E., et al. Estimation of the number of "true" null hypotheses in multivariate analysis of neuroimaging data. NeuroImage 2001, 13:920-930.
37. Turkheimer F.E., et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J. Nucl. Med. 2007, 48:158-167.
38. van Walderveen M.A., et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998, 50:1282-1288.
39. van Walderveen M.A., et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann. Neurol. 1999, 46:79-87.
40. van Walderveen M.A., et al. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. Arch. Neurol. 1999, 56:345-351.
41. Venneti S., et al. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. J. Neuropathol. Exp. Neurol. 2008, 67:1001-1010.
42. Vowinckel E., et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neurosci. Res. 1997, 50:345-353.
43. Yaqub M., et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies. J. Cereb. Blood Flow Metab. 2012, 32:1600-1608.